7.80
-0.28(-3.47%)
Currency In USD
| Previous Close | 8.08 |
| Open | 8 |
| Day High | 8.07 |
| Day Low | 7.76 |
| 52-Week High | 23.35 |
| 52-Week Low | 3.76 |
| Volume | 799,406 |
| Average Volume | 1.67M |
| Market Cap | 725.75M |
| PE | -1.81 |
| EPS | -4.31 |
| Moving Average 50 Days | 7 |
| Moving Average 200 Days | 7.91 |
| Change | -0.28 |
If you invested $1000 in Myriad Genetics, Inc. (MYGN) 10 years ago, it would be worth $190.24 as of October 20, 2025 at a share price of $7.8. Whereas If you bought $1000 worth of Myriad Genetics, Inc. (MYGN) shares 5 years ago, it would be worth $584.71 as of October 20, 2025 at a share price of $7.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendationsSALT LAKE CITY, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
GlobeNewswire Inc.
Sep 23, 2025 12:00 PM GMT
SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medic
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
GlobeNewswire Inc.
Sep 04, 2025 11:00 PM GMT
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad’